Related Experiment Video

Updated: Aug 22, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K

PAD4 and Its Inhibitors in Cancer Progression and Prognosis

Di Zhu1,2, Yu Lu1,2, Yanming Wang3

  • 1Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China.

Pharmaceutics
|November 11, 2022
PubMed

Insights

Peptidyl arginine deiminase 4 (PAD4) drives cancer growth, metastasis, and thrombosis. Inhibiting PAD4 shows promise for improving cancer treatment and patient outcomes.

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Systemic spread of malignancies and cancer-associated thrombosis are significant clinical challenges.
  • Peptidyl arginine deiminase 4 (PAD4) is a post-translational modification enzyme involved in protein citrullination.
  • PAD4 participates in gene regulation, neutrophil extracellular trap (NET), and macrophage extracellular trap (MET) formation.

Purpose of the Study:

  • To review PAD4's role in gene regulation, protein citrullination, and NET formation.
  • To discuss PAD4's involvement in cancer progression and cancer-associated thrombosis.
  • To summarize the development and application of PAD4 inhibitors for cancer therapy.

Main Methods:

  • Literature review of PAD4's functions and involvement in cancer.
  • Analysis of PAD4's role in cellular processes like citrullination and trap formation.
  • Summary of existing and developing PAD4 inhibitors.

Main Results:

  • PAD4 enhances primary tumor growth and distant cancer cell metastasis.
  • PAD4 is implicated in the pathogenesis of cancer-associated thrombosis.
  • PAD4 inhibitors represent a potential therapeutic strategy for cancer treatment.

Conclusions:

  • PAD4 is a key mediator in cancer progression and thrombosis.
  • Targeting PAD4 offers a promising avenue for novel cancer therapies.
  • PAD4 inhibitors may improve patient prognosis in cancer treatment.
Keywords:
NETosisPAD4PAD4 inhibitorcancercancer-associated thrombosiscitrullinationgene regulation

More Related Videos

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.2K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

489

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
419